ARTICLE SUMMARY:
Volta Medical is studiously advancing an AI-enabled support system for EPs performing cardiac ablation. The start-up recently finished enrollment in a randomized controlled trial called TAILORED-AF, which targets patients with the toughest kinds of persistent AF.
Pulmonary vein isolation (PVI) is the mainstay treatment for atrial fibrillation (AF). But the age-old question remains: for AF patients who aren’t fixed via PVI, particularly those with persistent AF, would outcomes improve if we could identify and treat triggers of AF elsewhere in the heart?
Answering that question has challenged clinical researchers and technology developers for decades. Of the numerous patterns of abnormal electrical activity that can be measured across the heart—focal signals, rotors, wavelets—which of them are temporary and which are stable? And where is the bull’s-eye, or the driver of AF?
